Shortening all-oral HCV therapy feasible

VIENNA – All-oral HCV therapy with grazoprevir and elbasvir plus sofosbuvir achieved high, sustained virologic response (SVR) rates at 12 weeks afte... More »

Field of Interest: Gastroentero...
Type: News Item

Add vitamin E to NASH ‘toolkit’

VIENNA – Pooled analysis of data from three controlled trials provides further evidence to support the use of vitamin E in the treatment of nonalcoh... More »

Field of Interest: Gastroentero...
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness